Related Experiment Video
Updated: Jul 9, 2025
Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
Published on: November 18, 2019
Mitophagy genes in ovarian cancer: a comprehensive analysis for improved immunotherapy
Wenting He1, Jieping Chen1, Yun Zhou1
1Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Background:
Mitophagy is a process of selectively degrading damaged mitochondria, which has been found to be related to immunity, tumorigenesis, tumor progression, and metastasis. However, the role of mitophagy-related genes (MRGs) in the tumor microenvironment (TME) of ovarian cancer (OV) remains largely unexplored.
Methods:
We analyzed the expression, prognosis, and genetic alterations of 29 MRGs in 480 OV samples. Unsupervised clustering was used to classify OV into two subtypes (clusters A and B) based on MRG changes. We compared the clinical features, differential expressed genes (DEGs), pathways, and immune cell infiltration between the two clusters. We constructed a mitophagy scoring system (MRG_score) based on the DEGs and validated its ability to predict overall survival of OV patients.
Results:
We found that patients with high MRG_scores had better survival status and increased infiltration by immune cells. Further analysis showed that these patients may be more sensitive to immune checkpoint inhibitor (ICI) treatment. Additionally, the MRG_score significantly correlated with the sensitivity of chemotherapeutic drugs and targeted inhibitors.
Conclusion:
Our comprehensive analysis of MRGs in the TME, clinical features, and patient prognosis revealed that the MRG_score is a potentially effective prognostic biomarker and predictor of treatment. This study provides new insights into the role of MRGs in OV and identifies patients who may benefit from ICI treatment, chemotherapy, or targeted treatment.
Insights
Mitophagy-related genes (MRGs) impact ovarian cancer (OV) progression. A new MRG score predicts better survival and treatment sensitivity, offering insights for immunotherapy and chemotherapy.
Area of Science:
- Mitochondrial biology
- Cancer research
- Immunology
Background:
- Mitophagy, the selective degradation of damaged mitochondria, is implicated in immunity and cancer.
- The role of mitophagy-related genes (MRGs) in the ovarian cancer (OV) tumor microenvironment (TME) is not well understood.
Purpose of the Study:
- To investigate the role of MRGs in the OV TME.
- To develop a prognostic biomarker for OV based on MRGs.
Main Methods:
- Analysis of 29 MRGs in 480 OV samples, including expression, prognosis, and genetic alterations.
- Unsupervised clustering to classify OV into subtypes based on MRG expression.
- Construction and validation of a mitophagy scoring system (MRG_score) to predict overall survival.
Main Results:
- High MRG_scores correlate with improved patient survival and increased immune cell infiltration.
- Patients with high MRG_scores may respond better to immune checkpoint inhibitor (ICI) therapy.
- The MRG_score predicts sensitivity to chemotherapy and targeted inhibitors.
Conclusions:
- The MRG_score serves as a potential prognostic biomarker and treatment predictor in OV.
- This study highlights the significance of MRGs in the OV TME and identifies patient subgroups for specific therapies.
- Findings suggest potential benefits of ICI, chemotherapy, or targeted treatments for patients with high MRG scores.
More Related Videos
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
